This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
Voluntary participation and written informed consent.
18-75 years old, no gender limitation.
Newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.
Confirmed tumor PD-L1 status prior to randomization.
Have untreated central nervous system metastasis; or have meningeal metastasis or spinal cord compression;
Uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites;
Previous or co-existing malignancies；
Have Active or prior documented autoimmune or inflammatory disorders;